
Replace Therapeutics
About Replace Therapeutics
Replace Therapeutics is a Healthcare company, and was acquired by Tome Biosciences in January 2024. CRISPR-based genome editing platform is developed for genetic diseases. Its chief executive, as recorded, is Shakked Halperin. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.
- Stage Acquired
- SectorsHealthcare
- Acquired by Tome Biosciences (Jan 2024)
- Investors
- Acquired byTome Biosciences
(Jan 2024)
Investors in Replace Therapeutics
Replace Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Tome Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRISPR-based gene insertion platform for genomic medicines is developed. | 2021 | tome.bio | Cambridge, United States |
Investor details for Replace Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Replace Therapeutics
1 people are tracked at Replace Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Shakked Halperin | CEO | Leadership |
Complete people profiles for Replace Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Replace Therapeutics
Shakked Halperin is the CEO of Replace Therapeutics, as recorded in our data.
A CRISPR-based genome editing platform is being developed by Replace Therapeutics for treating genetic diseases. Programmable genomic integration technology is utilized, combining the site-specificity of CRISPR and Cas9 with the DNA ligase enzyme to enable precise manipulation of small DNA sequences. Operations focus on biotechnology within the healthcare sector, with leadership provided by CEO Shakked Halperin.
Replace Therapeutics has 1 investor. Key investors include Tome Biosciences.
Yes. Replace Therapeutics was acquired by Tome Biosciences in January 2024.